As the number of conversations we’re having with scientists in validated environments increases year over year, we have found that a number of common misconceptions exist. Many arise because previous deployments of software accompanied the installation of new hardware, or have involved informatics systems that are intimately integrated across the development workflow and are the source of data and reports submitted directly to regulatory authorities. Below we clear up some of the grey areas that seem to have become industry myths that we commonly find ourselves correcting.
Structural Elucidations of NMR spectra, whether combined with other analytical techniques, or on their own, are akin to the challenges of the most complex cryptic crosswords—maybe the kind you find in the weekend editions of The Guardian, or The Times—but much, much tougher with some clues sometimes missing. At least that’s why I believe some of our internal experts and application scientists like the challenges of solving these “puzzles” on a regular basis.
With the help of ACD/Labs’ software, PharmaSea researchers have dereplicated more than 300 extracts, and, as a result, have identified 10 novel compounds that merit further research. Prof. Marcel Jaspars, head of the Marine Biodiscovery Centre at the University of Aberdeen, and project leader of PharmaSea, discusses the PharmaSea project in detail here.
Welcome to our company blog! We’re excited to announce the launch of this entirely new resource created specifically for our loyal ACD/Labs followers. Our posts will appear every few weeks, and they will include new thought provoking content, exclusive company news, and (most importantly) fun and entertaining updates from the ACD/Labs team. Considering today is our first post, we thought we’d start off with some good news! We’d like to take this opportunity to introduce Andrew Anderson, our new VP of Business Development. Andrew joins ACD/Labs from PepsiCo, Symyx before that, and…well… ACD/Labs.